Steatogenesis in adult-onset type II citrullinemia is associated with down-regulation of PPARα

• Published in: Biochimica et biophysica acta 2015-03, Vol.1852 (3), p.473-481
• Main Authors: Komatsu, Michiharu, Kimura, Takefumi, Yazaki, Masahide, Tanaka, Naoki, Yang, Yang, Nakajima, Takero, Horiuchi, Akira, Fang, Zhong-Ze, Joshita, Satoru, Matsumoto, Akihiro, Umemura, Takeji, Tanaka, Eiji, Gonzalez, Frank J., Ikeda, Shu-ichi, Aoyama, Toshifumi
• Format: Article
• Language: English
• Subjects: Adult; Citrullinemia - complications; Citrullinemia - genetics; Citrullinemia - metabolism; Citrullinemia - pathology; Down-Regulation; Fatty Acids - genetics; Fatty Acids - metabolism; Fatty Liver - etiology; Fatty Liver - genetics; Fatty Liver - metabolism; Fatty Liver - pathology; Female; Humans; JNK; JNK Mitogen-Activated Protein Kinases - genetics; JNK Mitogen-Activated Protein Kinases - metabolism; Ketone Bodies - genetics; Ketone Bodies - metabolism; Lipid Metabolism; Male; Middle Aged; Mitochondria, Liver - genetics; Mitochondria, Liver - metabolism; Mitochondria, Liver - pathology; Mitochondrial Membrane Transport Proteins; Mitochondrial β-oxidation; NAFLD; PPAR alpha - biosynthesis; PPAR alpha - genetics; PPARα; RNA, Messenger - biosynthesis; RNA, Messenger - genetics; SLC25A13; Triglycerides - genetics; Triglycerides - metabolism; Urea cycle disorder
• ISSN: 0925-4439; 0006-3002; 1879-260X; 1878-2434
• DOI: 10.1016/j.bbadis.2014.12.011

SLC25A13 (citrin or aspartate–glutamate carrier 2) is located in the mitochondrial membrane in the liver and its genetic deficiency causes adult-onset type II citrullinemia (CTLN2). CTLN2 is one of the urea cycle disorders characterized by sudden-onset hyperammonemia due to reduced argininosuccinate synthase activity. This disorder is frequently accompanied with hepatosteatosis in the absence of obesity and ethanol consumption. However, the precise mechanism of steatogenesis remains unclear. The expression of genes associated with fatty acid (FA) and triglyceride (TG) metabolism was examined using liver samples obtained from 16 CTLN2 patients and compared with 7 healthy individuals. Although expression of hepatic genes associated with lipogenesis and TG hydrolysis was not changed, the mRNAs encoding enzymes/proteins involved in FA oxidation (carnitine palmitoyl-CoA transferase 1α, medium- and very-long-chain acyl-CoA dehydrogenases, and acyl-CoA oxidase 1), very-low-density lipoprotein secretion (microsomal TG transfer protein), and FA transport (CD36 and FA-binding protein 1), were markedly suppressed in CTLN2 patients. Serum concentrations of ketone bodies were also decreased in these patients, suggesting reduced mitochondrial β-oxidation activity. Consistent with these findings, the expression of peroxisome proliferator-activated receptor α (PPARα), a master regulator of hepatic lipid metabolism, was significantly down-regulated. Hepatic PPARα expression was inversely correlated with severity of steatosis and circulating ammonia and citrulline levels. Additionally, phosphorylation of c-Jun-N-terminal kinase was enhanced in CTLN2 livers, which was likely associated with lower hepatic PPARα. Collectively, down-regulation of PPARα is associated with steatogenesis in CTLN2 patients. These findings provide a novel link between urea cycle disorder, lipid metabolism, and PPARα. •Hepatic expression of FA-oxidizing enzymes was suppressed in CTLN2 patients.•The expression of PPARα was significantly down-regulated in CTLN2 livers.•Hepatic PPARα was inversely correlated with circulating ammonia and citrulline.•Phosphorylation of c-Jun-N-terminal kinase was enhanced in CTLN2 livers.•A novel link between urea cycle disorder, lipid metabolism, and PPARα is proposed.